Hepatitis VA Rating

Hepatitis is one of the harder service-connection cases to win, and the reason is structural. The rating itself, under 38 CFR § 4.114, is fairly mechanical once entitlement is established: hepatitis B is rated under DC 7345, and hepatitis C keeps its own code, DC 7354, but is evaluated on the DC 7345 criteria. The fight usually lands on whether the virus can be tied to something that happened in service. A ruling is one issue the Board decided in one decision; one decision often rules on several issues. Across 2,366 decided Board rulings on hepatitis from 2021 to 2026, 18.1% were granted, 33.6% denied and 48.4% remanded. Denials outnumber grants, and most of these rulings are about service connection; the Board section below shows results by what the appeal asked for.

Chronic hepatitis C can progress slowly. A review estimated that 20 to 25 percent of people with it develop cirrhosis over 25 to 30 years (PMID 26600216), so a diagnosis can come decades after an in-service exposure, when the file shows nothing connecting the two. There is no presumption for hepatitis B or C, so every case rises or falls on a risk-factor analysis: blood exposure, combat medic or corpsman duties, transfusions before 1992, tattoos, shared razors, and jet air gun immunizations among them. One limit matters from the start: hepatitis that results from your own drug abuse in service cannot be service connected.

This page covers the current criteria and the transition rule for older claims, fatty liver, the risk factors VA recognizes, the C&P exam, separate ratings for cirrhosis and liver cancer, and why VA denies these claims.

TL;DR

• Hepatitis B is rated under 38 CFR § 4.114, DC 7345 (chronic liver disease without cirrhosis). Hepatitis C, and non-A, non-B hepatitis, is tracked under DC 7354 but evaluated on the DC 7345 criteria.
• DC 7354 no longer carries criteria. Since May 19, 2024 it reads "Rate under DC 7345 (Chronic liver disease without cirrhosis)."
• The "incapacitating episodes" framework is gone for current periods. For a claim pending across the change, the old criteria still govern the period before May 19, 2024, and VA uses whichever version is more favorable from that date.
• The current tiers are 0, 20, 40, 60, and 100 percent. The 100 percent rung is defined by treatment (parenteral antiviral plus parenteral immunomodulatory therapy, and for six months after they stop), not by symptoms.
• The 40 and 60 percent tiers are identical except for "minor" versus "substantial" weight loss. Serial weights in the record are what separate them.
• The 20 percent tier needs only one symptom, and it may be intermittent: fatigue, malaise, anorexia, hepatomegaly, or pruritus. No medication or weight-loss requirement.
• There is no presumptive service connection for hepatitis B or C. The claim depends on a documented in-service risk factor plus a medical opinion that weighs it against other risk factors. VA's adjudication manual lists jet air gun immunization among the recognized risk factors.
• Sequelae such as cirrhosis and liver cancer are rated under their own codes, without using the same symptoms twice.
• Across 2,366 decided Board rulings on hepatitis from 2021 to 2026, 18.1% were granted, 33.6% denied and 48.4% remanded. Remand is the most common outcome, and the grant rate is 6.6 points below the Board-wide 24.7 percent.

Hepatitis VA rating criteria (DC 7345 and DC 7354)

Hepatitis C, and non-A, non-B hepatitis, still has its own diagnostic code at 38 CFR § 4.114, DC 7354, but that code no longer carries criteria. Since the digestive-system rewrite published March 20, 2024 (89 FR 19735) and effective May 19, 2024, the entry reads in full as follows.

7354 Hepatitis C (or non-A, non-B hepatitis): Rate under DC 7345 (Chronic liver disease without cirrhosis).

So the code on your decision may still read 7354, while the criteria being applied are DC 7345's. Here is the current DC 7345 text.

Progressive chronic liver disease requiring use of both parenteral antiviral therapy (direct antiviral agents), and parenteral immunomodulatory therapy (interferon and other); and for six months following discontinuance of treatment, 100%

Progressive chronic liver disease requiring continuous medication and causing substantial weight loss and at least two of the following: (1) daily fatigue, (2) malaise, (3) anorexia, (4) hepatomegaly, (5) pruritus, and (6) arthralgia, 60%

Progressive chronic liver disease requiring continuous medication and causing minor weight loss and at least two of the following: (1) daily fatigue, (2) malaise, (3) anorexia, (4) hepatomegaly, (5) pruritus, and (6) arthralgia, 40%

Chronic liver disease with at least one of the following: (1) intermittent fatigue, (2) malaise, (3) anorexia, (4) hepatomegaly, or (5) pruritus, 20%

Previous history of liver disease, currently asymptomatic, 0%

Three structural points follow, and they change how a claim should be built.

Treatment is now the top of the ladder. The 100 percent tier is a treatment description: parenteral antiviral therapy and parenteral immunomodulatory therapy, both, plus six months after they stop. Note (1) requires a mandatory VA examination at the end of that six months, with § 3.105(e) protections applying to any change that follows.

The middle of the ladder splits on weight loss. The 60 and 40 percent tiers are the same sentence except for one word: "substantial" weight loss versus "minor" weight loss. Both require continuous medication and two or more findings from the same six-item list, so the documented weight trend is the single fact separating a 40 from a 60.

The 20 percent tier is much easier to reach than it looks. It requires chronic liver disease with at least one of intermittent fatigue, malaise, anorexia, hepatomegaly, or pruritus. There is no medication requirement and no weight-loss requirement at this rung.

At the 2026 rates for a veteran alone, 20 percent pays $356.66 a month, 40 percent $795.84, 60 percent $1,435.02 and 100 percent $3,938.58.

Two more notes matter. Note (2) provides that where physicians recommend both parenteral antiviral therapy and parenteral immunomodulatory drugs but treatment is medically contraindicated, VA rates under DC 7312 (cirrhosis of the liver) instead. Note (4) directs that sequelae such as cirrhosis or liver malignancy be rated under their own codes, but bars using the same signs and symptoms twice, per § 4.14.

A veteran whose hepatitis C has been cured presents a separate question. Direct-acting antiviral drugs now cure most chronic hepatitis C; a meta-analysis found a pooled cure rate (sustained virologic response) of 93.3 percent in patients without liver cancer (PMID 31096005). The 0 percent tier is "previous history of liver disease, currently asymptomatic," and once the virus is cleared and symptoms resolve, that is the rung the schedule points to. Cure does not erase a service-connected diagnosis, and it does not foreclose a compensable rating where a qualifying symptom persists, since the 20 percent tier needs only one intermittent symptom. Residual liver damage and sequelae have to be documented on their own terms under Note (4).

Hepatitis B and hepatitis C: which code applies

DC 7354 covers hepatitis C and non-A, non-B hepatitis. Note (3) to DC 7345 says that code includes "Hepatitis B (confirmed by serologic testing)," along with conditions such as autoimmune liver disease, drug-induced hepatitis, and non-alcoholic steatohepatitis. Since May 19, 2024, both codes use the same criteria, so the code mainly identifies the diagnosis rather than changing the rating math. In a June 2025 decision, the Board assigned 40 percent for hepatitis B with daily fatigue, malaise, anorexia, and minor weight loss, but not substantial weight loss (Citation Nr. A25051064).

The practical point: the serology in the record should be clear. A diagnosis of "hepatitis" without specifying B versus C, or acute versus chronic, invites a rating analysis that misses the right code or leaves the rater unsure that chronic liver disease is established.

Which hepatitis criteria apply to a pending claim

Before May 19, 2024, hepatitis was rated on a different set of tiers that turned largely on incapacitating episodes, defined in the old rule, as the Board quotes it, as "a period of acute signs and symptoms severe enough to require bed rest and treatment by a physician" (Citation Nr. A25003281). Bed rest alone was not enough, and a physician visit alone was not enough; the episode needed both, and it had to be documented.

• If VA decided your claim before May 19, 2024, the old criteria applied to that decision.
• If your claim or appeal was pending when the rule changed, VA applies the old criteria to the period before May 19, 2024. From May 19, 2024 on, it considers both the old and the new criteria and uses whichever is more favorable to you. The new criteria cannot be applied to any period before their effective date. Board decisions on hepatitis cite 38 U.S.C. § 5110(g) and Kuzma v. Principi, 341 F.3d 1327 (Fed. Cir. 2003), for this rule (Citation Nr. A25003281).

For those earlier periods, the evidence that counts is contemporaneous. A treatment note that says "advised bed rest" during a symptomatic flare, with the physician's involvement documented, supports the episode count. Symptom journals that log the dates and duration of flares, cross-referenced against medical visits, help the rater reconstruct the 12-month picture instead of guessing at it. For current periods, the equivalent evidence is a record that names the six findings, the weight trend, and the medication history the DC 7345 tiers use.

Fatty liver and non-alcoholic steatohepatitis

A report of fatty liver does not automatically establish a compensable VA disability. Clarify the diagnosed liver disease and its symptoms. DC 7345 specifically includes non-alcoholic steatohepatitis (NASH), which is distinct from viral hepatitis. Evidence about a hepatitis infection's transmission does not establish the service connection for a different liver disease.

Your records should identify the diagnosis, treatment, relevant symptoms, and any cirrhosis. The current chronic-liver criteria on this page explain the rating framework when DC 7345 applies. For any proposed connection to a service-connected condition or medication, a clinician must explain causation or aggravation in your case; coexistence with diabetes alone does not establish that link. Where the opinion does that work, the Board has granted it: in a May 2025 decision, it granted a liver condition including hepatic steatosis (fatty liver) and cirrhosis as secondary to service-connected hepatitis B (Citation Nr. A25045316).

Sources: 38 CFR § 4.114, DC 7345 Note (3) (opens in a new tab) and § 3.310, secondary service connection (opens in a new tab).

How to prove hepatitis C is service connected

This is the part of the hepatitis claim that decides most cases. Hepatitis C has no presumptive pathway, so you have to show a current diagnosis, an in-service event or risk factor, and a medical nexus linking the two.

No statute or regulation lists hepatitis C risk factors, but VA's adjudication manual does, and the Board relies on it. As the Board summarized it in a March 2025 decision, the M21-1 (Part V, Subpart iii, Chapter 6) lists these risk factors (Citation Nr. 25003838).

• Transfusion of blood or a blood product before 1992
• Organ transplant before 1992
• Hemodialysis
• Tattoos and body piercing
• Intravenous drug use and intranasal cocaine use, with shared instruments
• High-risk sexual activity
• Accidental exposure to blood as a health care worker, combat medic, or corpsman, through the skin or a mucous membrane
• Other direct exposure to blood through the skin, such as acupuncture with non-sterile needles or shared toothbrushes or razors
• Immunization with a jet air gun injector

Jet air gun immunizations. The manual lists them, so they are a recognized theory, not an automatic grant. Examiners in the 2025 decisions I read describe air gun transmission as biologically plausible but thinly documented, and the Board weighs it against your other risk factors; in a May 2025 denial, the examiner found the veteran's other risk factors more likely than the air gun (Citation Nr. 25006286). An opinion that calls the air gun "plausible" without explaining why it is or is not outweighed is too speculative to decide the claim, and the Board sends it back (Citation Nr. 25007917).

Blood exposure and combat. Treating wounded service members, handling casualties, and medic or corpsman duties create documented blood exposure. For combat veterans, 38 U.S.C. § 1154(b) lets your own account of a combat exposure establish it. In a January 2025 decision, the Board granted hepatitis C for a veteran who described exposure to blood while giving aid to a wounded soldier in combat, along with air gun vaccinations and tattoos (Citation Nr. 25000692).

Drug use is a limit, not a lane. Hepatitis that results from drug abuse in service is not incurred in the line of duty and cannot be service connected, and the regulation defines drug abuse to include the use of illegal drugs (38 CFR § 3.301(d)). The residuals of venereal disease are treated differently and are not willful misconduct (§ 3.301(c)(1)); in the March 2025 decision above, the Board granted hepatitis C on in-service high-risk sexual activity documented by treatment records (Citation Nr. 25003838).

Weighing the factors. When the evidence for an in-service risk factor is about equal to the evidence for a pre-service or post-service one, the tie goes to you (Andrews v. McDonough, 34 Vet. App. 216 (2021)). The probative opinion identifies the in-service risk factor, weighs it against any competing risk factors, and explains why the in-service factor is at least as likely as not the source. A bare statement that you "could have" been infected by a jet injector is not enough.

The hepatitis C&P exam

The hepatitis C&P exam follows the DBQ for hepatitis, cirrhosis, and other liver conditions, and it does double duty: it has to support both the nexus and the severity rating.

For the nexus, the examiner should take a full risk-factor history covering both in-service and post-service exposures, review the service treatment records and personnel file, and give an opinion that weighs the in-service factors against competing causes with a stated rationale. An exam that records "veteran has hepatitis C" and offers a conclusory negative opinion is the kind the Board sends back. Before the exam, put a detailed lay statement in the file describing every plausible in-service exposure, with service records and buddy statements that corroborate it where possible. An evidence checklist for hepatitis claims should separate the diagnosis, the in-service risk factor, the nexus opinion, and the severity documentation into their own proof lanes.

For severity, the examiner records which of the six named findings are present (daily fatigue, malaise, anorexia, hepatomegaly, pruritus, arthralgia), the weight trend and whether any loss is minor or substantial, whether you take continuous medication, and whether parenteral antiviral and immunomodulatory therapy is or was in use and when it stopped. Liver function tests, viral load, imaging, and whether the virus has been cleared round out the picture. A symptom tracker for hepatitis flares that logs which findings occur and how often helps, but the highest-value records are serial weights and the medication history. Use C&P exam prep for the hepatitis DBQ so the examiner has facts to record rather than a single-day snapshot.

The Board section below shows what happened to hepatitis service connection claims when the Board relied on a favorable opinion, an opinion against the claim, or no opinion at all. Those categories record what the Board credited, not grades of evidence quality. When the exam is inadequate, the Board's usual move is a remand for a corrected exam rather than an outright grant or denial.

Cirrhosis, liver cancer and other hepatitis sequelae

Chronic hepatitis C can progress to cirrhosis and liver cancer (PMID 26600216), and Note (4) to DC 7345 treats both as sequelae rated under their own diagnostic codes rather than folded into the hepatitis rating. In a January 2025 decision, the Board granted cirrhosis and liver cancer as due to service-connected hepatitis C (Citation Nr. 25000692).

That matters for two reasons. First, it can raise the combined rating: active hepatitis C rated under DC 7354 and separately documented cirrhosis under DC 7312 can carry a higher combined evaluation than the hepatitis rating alone. Second, it shifts the evidentiary focus. The sequela has to be documented as a distinct diagnosis with its own findings, and its service connection flows through the underlying hepatitis under 38 CFR § 3.310, which covers conditions caused or aggravated by a service-connected condition.

Two limits apply. The pyramiding rule under 38 CFR § 4.14 bars rating the same symptom twice, so the cirrhosis rating has to rest on findings separate from the hepatitis rating. And for hepatitis B, which is rated under DC 7345 itself, the opening paragraph of § 4.114 bars combining DC 7345 with DC 7312; VA assigns one rating under the code for the predominant disability and can raise it one level when the overall picture is more severe. Liver cancer under DC 7343 is outside that bar.

Why VA denies hepatitis claims

When the Board denied hepatitis service connection, the part it most often found missing was a link to service, followed by an in-service event or exposure and then a current diagnosis. When it remanded, the most common reason was an inadequate VA exam or opinion. The Board section below shows how often each part failed and why claims were sent back. These are the patterns I see across the decisions.

No risk-factor narrative in the file. The veteran has a confirmed hepatitis C diagnosis, but nothing in the record connects it to service: no statement about jet air gun immunizations, blood exposure, medic duties, transfusions, or tattoos. Without a stated in-service risk factor, the examiner has nothing to opine on and the claim defaults to denial.

Nexus opinion that ignores competing causes. An opinion that addresses the in-service factor in isolation, or dismisses it without explaining why a competing cause is more likely, is not probative, and the Board says so on remand.

The infection traces to in-service drug use. When the record and the opinions point to drug use in service as the source, § 3.301(d) bars service connection even though the infection began in service.

No current diagnosis, or an unclear one. A diagnosis of "hepatitis" without serology distinguishing B from C, or acute from chronic, can push the claim into the wrong code or leave the rater unsure that chronic liver disease is established.

Severity findings not documented. For current periods, a record that never names the six findings, the weight trend, or the medication history the DC 7345 tiers use. For periods before May 19, 2024, flares that were never tied to physician-documented bed rest.

Sequelae left unrated. Cirrhosis or liver cancer in the record but never separately claimed or rated.

From 2,366 decided Board rulings on hepatitis from 2021 to 2026, 18.1% were granted, 33.6% were denied and 48.4% were remanded. Denials outnumber grants and remands outnumber both, which is the fingerprint of a nexus problem rather than a severity problem. The Board section below also shows how direct, secondary, and presumptive claims fared. Those are associations, not causes. The cases that succeed tend to have a clear, documented in-service risk factor and a nexus opinion that actually weighs it against the alternatives.

Questions veterans ask about hepatitis

What is the VA disability rating for hepatitis B?

Hepatitis B is rated under DC 7345 at 0, 20, 40, 60, or 100 percent. One intermittent symptom such as fatigue supports 20 percent, continuous medication with weight loss and two listed findings supports 40 or 60 percent, and 100 percent is tied to parenteral antiviral plus immunomodulatory treatment.

Is hepatitis C a presumptive condition for veterans?

No. Hepatitis C is not on any presumptive list, so you need a current diagnosis, an in-service risk factor, and a medical opinion linking the two.

Can air gun vaccinations support a hep C VA claim?

Yes, as a theory to develop. VA's adjudication manual lists jet air gun immunization as a hepatitis C risk factor, but the opinion has to weigh it against your other risk factors and explain why service is at least as likely as not the source.

Does cured hepatitis C still get a VA rating?

Service connection stays, but the rating follows your current findings. With no symptoms, the schedule points to 0 percent; one intermittent qualifying symptom supports 20 percent, and cirrhosis or other damage is rated on its own.

Can hepatitis from drug use in service be service connected?

No. Under 38 CFR § 3.301(d), a disease that results from drug abuse in service, including the use of illegal drugs, is not incurred in the line of duty, so it cannot be service connected.

What does VA need for a hep C claim?

VA needs serology confirming chronic hepatitis C, evidence of an in-service risk factor such as blood exposure, medic duties, a transfusion before 1992, or air gun immunizations, and a medical opinion that weighs that factor against any others.

Bottom Line

Hepatitis claims are not primarily a rating problem. The DC 7345 criteria, which hepatitis B uses directly and hepatitis C uses through DC 7354, are mechanical once entitlement is established, and they turn on named symptoms, weight loss, continuous medication, and treatment. The reason denials outnumber grants in Board hepatitis rulings, 33.6 percent against 18.1 percent of decided rulings, is the nexus: there is no presumptive pathway, the disease can surface decades after exposure, and the claim lives or dies on whether the record ties the infection to an in-service risk factor that VA recognizes, such as blood exposure, medic duties, transfusions, tattoos, or jet air gun immunizations, without tracing it to drug use in service. The cases that win have a documented risk factor and a nexus opinion that weighs it against competing causes. On severity, document the named findings, the weight trend, and the medication and treatment history, and rate any cirrhosis or liver cancer separately rather than leaving the downstream damage out of the analysis.

Related Conditions

Hepatitis claims share rating and proof logic with other systemic and organ conditions. The secondary and severity dynamics overlap with kidney disease, where organ-function documentation and separate rating of complications matter, and with diabetes, another systemic condition where the nexus and the downstream complications drive the combined rating. Veterans with hepatitis that has progressed to liver damage should review the secondary conditions tool before assuming the hepatitis rating alone tells the whole story.

Methodology and Limitations

• Data source: Rating criteria quoted verbatim from the current 38 CFR § 4.114 as amended by the final rule "Schedule for Rating Disabilities: The Digestive System," 89 FR 19735, published 2024-03-20, effective 2024-05-19, checked against the eCFR text in October 2026. DC 7354 (hepatitis C and non-A, non-B hepatitis) now directs "Rate under DC 7345 (Chronic liver disease without cirrhosis)," so the tier text quoted here is DC 7345's. Per Note (3) to DC 7345, hepatitis B is also evaluated there. Pyramiding from § 4.14 and the combining rule in the opening paragraph of § 4.114. Secondary service connection from § 3.310. Line-of-duty rules from § 3.301. Risk factors from the M21-1 list as the Board quotes it, with Andrews v. McDonough on weighing them. Board decisions cited by citation number come from the 2025 Board decision files. Medical statements cite PubMed abstracts by PMID.
• Sample size: Patterns in this post are drawn from Claim Raven's read of every Board decision from 2021 to 2026 that it holds: 511,036 decisions containing 1,378,030 rulings, including 2,622 Board rulings on hepatitis (2,366 decided). Within that hepatitis subset, outcomes ran 33.6% denied (794 rulings), 48.4% remanded (1,144 rulings), and 18.1% granted (428 rulings). The Board section on this page breaks these down by denial reason, remand reason, appeal type, medical opinion, claim theory and era; those figures are computed from the data, not typed here. The read does not code rating tiers or split hepatitis B from hepatitis C.
• Classification approach: Diagnostic code definitions drawn from the current regulatory text. The nexus and risk-factor analysis follows the M21-1 risk factors and the way the Board applies them. Severity analysis follows the current DC 7345 tiers; the incapacitating-episode discussion is retained for claim periods before May 19, 2024.
• Limitations:
• Much of the 2021 to 2026 window predates the criteria on this page. Decisions before May 19, 2024 applied the old criteria, whose tiers ran largely on incapacitating episodes, and a later decision can still apply the old criteria to the period before the change. I have not split these rulings by which criteria the Board applied, so the outcome rates describe a mix of the two standards. The nexus findings, which drive most of these cases, are unaffected by the rating-criteria change.
• The current criteria leave "substantial" versus "minor" weight loss undefined, and that single word is the line between 40 and 60 percent.
• Hepatitis B and C have no presumptive service-connection pathway. Every case turns on a fact-specific risk-factor and nexus analysis, so outcomes vary widely with the quality of the record.
• The jet air gun immunization theory is listed by VA as a risk factor, but it is contested and fact-specific, not an automatic grant.
• The Board decisions cited here are examples of how the rules are applied, not a count of how often each outcome occurs.
• Compensation amounts reflect the 2026 VA rate tables (effective December 1, 2025) for a single veteran with no dependents and change annually with COLA.
• Selection bias: BVA-level patterns reflect cases that appealed. Most hepatitis claims resolve at the RO level and are not in any BVA dataset.
• These observations reflect patterns from the regulatory text, case law, and BVA decisions. They are not predictions of individual outcomes.